Sherene Loi

机构：Peter MacCallum Cancer Centre

发表论文 11 篇 · 总被引 358 次 · h-index 5

代表论文

• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021 · npj Breast Cancer · 被引 282)
• Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 (2024 · Journal of Clinical Oncology · 被引 23)
• INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). (2025 · Journal of Clinical Oncology · 被引 20)
• 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS. (2025 · Journal of Clinical Oncology · 被引 18)
• Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens (2025 · JAMA Oncology · 被引 6)
• Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC) (2025 · Cancer Research · 被引 5)